US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

25.22

+0.33001.33%

Post-market: 25.220.00000.00%19:59 EDT

Volume:441.50K

Turnover:11.11M

Market Cap:862.84M

PE:-6.66

High:25.58

Open:25.10

Low:24.55

Close:24.89

Loading ...

Overview Company News Filings

ArriVent Biopharma Inc. Conducted Annual Stockholders Meeting

Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success

Optimistic Outlook for ArriVent BioPharma, Inc. Amid Promising Developments and Market Support

Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates

ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.

Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $40 From $39

THOMSON REUTERS

Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results

Arrivent Biopharma Inc expected to post a loss of 66 cents a share - Earnings Preview

Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

new option listings on April 9th

ArriVent BioPharma Initiated at Buy by Guggenheim

Guggenheim Initiates ArriVent BioPharma at Buy With $45 Price Target

MT Newswires Live

ArriVent BioPharma Price Target Maintained With a $39.00/Share by HC Wainwright & Co.

ArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy Rating

ArriVent BioPharma Reports 2024 Financial Results and Progress

ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024

Arrivent Biopharma Inc - Expects Cash to Fund Operations Into 2026

THOMSON REUTERS

ArriVent BioPharma Reports Full Year 2024 Financial Results

Arrivent Biopharma Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":25.22,"timestamp":1750449600000,"preClose":24.89,"halted":0,"volume":441503,"hourTrading":{"tag":"盘后","latestPrice":25.22,"preClose":25.22,"latestTime":"19:59 EDT","volume":40741,"amount":1027487.4568,"timestamp":1750463969105},"delay":0,"floatShares":15821834,"shares":34212561,"eps":-3.784111,"marketStatus":"Market Closed","change":0.33,"latestTime":"06-20 16:00:00 EDT","open":25.1,"high":25.58,"low":24.55,"amount":11109069.346802,"amplitude":0.041382,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.784111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":24.89,"postHourTrading":{"tag":"盘后","latestPrice":25.22,"preClose":25.22,"latestTime":"19:59 EDT","volume":40741,"amount":1027487.4568,"timestamp":1750463969105},"volumeRatio":0.996611,"impliedVol":0.1873,"impliedVolPercentile":0.06},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":15821834,"roa":"-23.10%","roe":"-49.00%","lyrEps":-2.557665,"volumeRatio":0.996611,"shares":34212561,"dividePrice":0,"high":25.58,"amplitude":0.041382,"preClose":24.89,"low":24.55,"week52Low":15.47,"pbRate":"4.26","week52High":36.37,"institutionHeld":0,"latestPrice":25.22,"eps":-3.784111,"divideRate":0,"volume":441503,"delay":0,"ttmEps":-3.784111,"open":25.1,"prevYearClose":26.64,"prevWeekClose":23.27,"prevMonthClose":21.25,"prevQuarterClose":18.49,"fiveDayClose":23.63,"twentyDayClose":20.47,"sixtyDayClose":18.99},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545170292","title":"ArriVent Biopharma Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170292?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:15","pubTimestamp":1750450512,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL1kPGYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2544198892","title":"Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2544198892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544198892?lang=en_us&edition=fundamental","pubTime":"2025-06-17 04:05","pubTimestamp":1750104312,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report). The associated price targ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-arrivent-biopharma-amid-strong-stock-momentum-and-anticipated-trial-success-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-arrivent-biopharma-amid-strong-stock-momentum-and-anticipated-trial-success-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2542933521","title":"Optimistic Outlook for ArriVent BioPharma, Inc. Amid Promising Developments and Market Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2542933521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542933521?lang=en_us&edition=fundamental","pubTime":"2025-06-09 23:15","pubTimestamp":1749482120,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report), retaining the price target of $40....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-arrivent-biopharma-inc-amid-promising-developments-and-market-support-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-arrivent-biopharma-inc-amid-promising-developments-and-market-support-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2539694267","title":"Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2539694267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539694267?lang=en_us&edition=fundamental","pubTime":"2025-05-30 00:55","pubTimestamp":1748537719,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) and keeping the price target at $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-arrivent-biopharma-buy-rating-justified-by-upcoming-egfr-pacc-mutant-nsclc-program-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-arrivent-biopharma-buy-rating-justified-by-upcoming-egfr-pacc-mutant-nsclc-program-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PACC","AVBP"],"gpt_icon":0},{"id":"2535056970","title":"ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535056970","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535056970?lang=en_us&edition=fundamental","pubTime":"2025-05-15 01:37","pubTimestamp":1747244220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2025 13:37 ET (17:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2535004629","title":"Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $40 From $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2535004629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535004629?lang=en_us&edition=fundamental","pubTime":"2025-05-14 18:21","pubTimestamp":1747218094,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nAZN3TXIOZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2534722462","title":"Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534722462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534722462?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in global pivotal Phase 3 study for firmonertinib. monotherapy in first-line NSCLC harboring EGFR exon 20 insertion. -- Planned update for development of firmonertinib in first-line NSCLC PACC. -- First IND for ARR-217 , an antibody drug conjugate . -- Cash, cash equivalents and marketable securities of $205.5 million as of. \"We continued our strong execution across our oncology-focused pipeline and are preparing for several near-term milestones. Importantly, our late-stage firmonertinib program continues to show differentiated potential to address unmet needs across EGFR-mutant non-small cell lung cancer ,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"ARR-217 , our recently acquired antibody drug conjugate  targeting the gastrointestinal marker CDH17 with best-in-class potential, is expected to be the first ADC from our pipeline to enter the clinic.\". -- Completed enrollment for pivotal trial. During the first quarter of 2025,we completed e","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","PACC","BK4139","BK4211","BK4080","AVBP","ADC","BK4231"],"gpt_icon":0},{"id":"2533831725","title":"Arrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533831725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533831725?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:33","pubTimestamp":1746444791,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc  expected to post a loss of66cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2530039724","title":"Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039724","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039724?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWTOWN SQUARE, Pa., April 28, 2025  -- ArriVent BioPharma, Inc.  , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.\"Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies across a broad array of therapeutic areas,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"We are thrilled to have him join our Board of Directors at this important time and leverage his experience as firmonertinib progresses towards registration and we advance our antibody drug conjugate  pipeline.\". ArriVent is a clinical-stage biopha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2526636636","title":"new option listings on April 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2526636636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526636636?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201816,"startTime":"0","endTime":"0","summary":"New option listings for April 9th include Alumis Inc (ALMS), LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG), Arrivent Biopharma Inc (AVBP), REX BITC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FDN","BK4147","LU0345774391.USD","BK4139","BK4550","ALMS","BK4007","IE0004445239.USD","LU1734074674.USD","03165","BK4543","LU0823434583.USD","ASMG","AVBP","LU2063271972.USD","LU0823434740.USD","IE00BD6J9T35.USD","LU0097036916.USD","BK4585","LU0345774631.USD","BK4588"],"gpt_icon":0},{"id":"2518279685","title":"ArriVent BioPharma Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518279685?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:11","pubTimestamp":1741619460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 11:11 ET (15:11 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2518280592","title":"Guggenheim Initiates ArriVent BioPharma at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2518280592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518280592?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:06","pubTimestamp":1741608411,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"2517438614","title":"ArriVent BioPharma Price Target Maintained With a $39.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438614?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:45","pubTimestamp":1741351500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:45 ET (12:45 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2517462486","title":"ArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517462486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517462486?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:28","pubTimestamp":1741346931,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) today and set a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-clinical-trials-and-market-potential-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-clinical-trials-and-market-potential-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2516238616","title":"ArriVent BioPharma Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2516238616","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516238616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 12:03","pubTimestamp":1741061018,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q4 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","AVBP","BK4097","BK4139","LU2065732104.USD"],"gpt_icon":0},{"id":"2516680176","title":"ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680176","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680176?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:20","pubTimestamp":1741004442,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44073766/arrivent-biopharma-2024-net-loss-80-5m-cash-cash-equivalent-and-investments-of-266-5m-as-of-dec-31-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2516687078","title":"Arrivent Biopharma Inc - Expects Cash to Fund Operations Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687078?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:10","pubTimestamp":1741003801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2516168726","title":"ArriVent BioPharma Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168726","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516168726?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonert","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035450/0/en/ArriVent-BioPharma-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","AVBP","PACC","BK4231","BK4139"],"gpt_icon":0},{"id":"2508112355","title":"Arrivent Biopharma Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112355","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112355?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:06","pubTimestamp":1738584399,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2505510097","title":"ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2505510097","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505510097?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:05","pubTimestamp":1737633950,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on ArriVent Biopharma  to $39 from $36 and keeps a Buy rating on the shares after the company entered into an exclusive license agreement with Lepu Biopharma. The firm says ArriVent’s portfolio continues to broaden with the MRG007 license.Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.ArriVent BioPharma Expands Oncology Pipeline with New License","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/arrivent-biopharma-price-target-raised-120550197.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrivent-biopharma-price-target-raised-120550197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"AVBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.9},{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-11-14","symbol":"AVBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1747800000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2025-06-18","current":-6.705187,"percent":0.927492,"low":-15.980041,"twenty":-11.848555,"median":-10.362882,"eighty":-8.152944,"high":-5.032917,"avg":-9.974088,"sd":2.196087,"marketCap":854629773},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-18","current":-6.705187,"twenty":-11.848555,"median":-10.362882,"eighty":-8.152944,"marketCap":854629773}],"updateTime":1750458518938}}}